(NASDAQ: ALGS) Aligos Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41.92%.
Aligos Therapeutics's earnings in 2025 is -$74,184,000.On average, 6 Wall Street analysts forecast ALGS's earnings for 2025 to be -$49,442,284, with the lowest ALGS earnings forecast at -$49,372,158, and the highest ALGS earnings forecast at -$49,152,554. On average, 6 Wall Street analysts forecast ALGS's earnings for 2026 to be -$42,937,821, with the lowest ALGS earnings forecast at -$47,804,788, and the highest ALGS earnings forecast at -$32,036,356.
In 2027, ALGS is forecast to generate -$42,519,527 in earnings, with the lowest earnings forecast at -$58,173,544 and the highest earnings forecast at -$24,996,108.